Optum Health Solutions (UK) Ltd agreed to acquire EMIS Group plc (AIM:EMIS) from a group of shareholders for £1.2 billion on April 8, 2022. As of June 17, 2022, Optum Health Solutions (UK) Ltd reached an agreement to acquire EMIS Group plc (AIM:EMIS) from a group of shareholders. The Acquisition will be fully funded through UnitedHealth Group's existing cash resources. In addition, Octopus Investments Ltd and Evenlode Investment Management Ltd has given to Bidco a non-binding letter of intent to vote in favour of the Scheme. On July 25, 2022, Octopus had disposed of 406,688 Shares and is therefore no longer in a position to vote or procure the voting of the disposed Shares in favor of the Offer. Now, Octopus's intention in respect of 5,618,844 Shares.

The transaction is subject to approval by shareholders of EMIS Group plc, regulatory, CMA and court approvals and is expected to close before the end of 2022. EMIS directors intend to unanimously recommend that shareholders vote in favour of the deal. As of August 8, 2022, the transaction has received approval from court and EMIS Group plc shareholders in general meeting. As of November 1, 2022, As regards the remaining substantive regulatory condition to the Acquisition, Bidco and EMIS are in the process of finalising a Merger Notice with the Competition and Markets Authority ("CMA"), preliminary to a Phase One investigation of the Acquisition. As a result, unless the relevant condition is waived by Bidco, EMIS now expects the Scheme to become Effective in the first quarter of 2023. As of March 17, 2023, An initial investigation by the Competition and Markets Authority (CMA) has found UnitedHealth's deal to buy EMIS could reduce competition leading to worse outcomes for the NHS and ultimately patients and UK taxpayers. UnitedHealth and EMIS have 5 working days to offer legally binding proposals to the CMA to address the concerns identified. The CMA would then have a further 5 working days to consider whether this address its concerns, or if the case should be referred to the next stage, Phase 2 investigation. Bidco, with the full support of EMIS, submitted a proposed remedy to the CMA to address the CMA's competition concerns in lieu of a Phase 2 reference. As of April 6, 2023, Emis and Bordeaux UK agree to extend the long stop date for completion of Emis' acquisition to June 30, 2024. As of May 24, 2023, the Court has approved the extension of the Long Stop Date to June 30, 2024, and the Scheme remains subject to the sanction by the Court at the Court Hearing and the satisfaction (or, where applicable, the waiver) of the Conditions to the Scheme. As of August 11, 2023, Competition and Markets Authority has provisionally cleared the transaction. The CMA has provisionally cleared the acquisition and has set a September 1 deadline for interested parties to submit responses. The CMA will announce its final decision on October 5, 2023. As of September 29, 2023 the Boards are pleased to confirm that all of the Conditions to the Acquisition relating to regulatory approvals have now been satisfied. As of September 29, 2023 Competition and Markets Authority has approved the transaction.

Simon Willis, James Black, Joshua Hughes and Havish Patel of Numis Securities Limited acted as financial advisor and Richard Spedding, Stephen Whitfield and Elissavet Grout of Travers Smith LLP acted as legal advisor to EMIS Group plc. Simon Warshaw and Philip Apostolides of Robey Warshaw LLP acted as financial advisor and Slaughter and May acted as legal advisor to Optum Health Solutions (UK) Ltd and UnitedHealth Group Incorporated.

Optum Health Solutions (UK) Ltd completed the acquisition EMIS Group plc (AIM:EMIS) from a group of shareholders on October 25, 2023. As on October 25, 2023, The High Court of Justice in England and Wales had sanctioned the Scheme at the Court Sanction Hearing held on date, the Court Order has been delivered to the Registrar of Companies, the Scheme has now become effective in accordance with its terms and the entire issued, and to be issued, share capital of EMIS is now owned by Bidco. Upon the Scheme becoming effective, the resignations of the EMIS Non-Executive Directors, Patrick De Smedt, Denise Collis, Jennifer Byrne, Kevin Boyd and Jayaprakasa (JP) Rangaswami, took effect. Andy Thorburn and Peter Southby will remain on the EMIS Board. As previously advised, trading in EMIS Shares on AIM is expected to be suspended today and the cancellation of trading of EMIS Shares on AIM is expected to take place on October 30, 2023. As of October 30, 2023, London Stock Exchange has cancelled the listing of EMIS Shares on AIM and has cancelled the trading of EMIS Shares on the London Stock Exchange's AIM Market, in each case with effect October 30, 2023.